A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone)

Medivation, Inc.0 个研究点目标入组 150 人开始时间: 2018年1月9日最近更新: 2023年8月21日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Medivation, Inc.
入组人数: 150

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: Male

入选标准

•-At least 18 years of age and willing and able to provide informed consent.
•- Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell, or small cell features.
•- Consent to a fresh tumor biopsy before enrollment unless adequate archival tissue is available for molecular analyses. Consent to blood sample collection for germline DNA and biomarker analysis is required.
•If the patient does not have a prior histologic diagnosis, a baseline fresh tumor biopsy may be used for both the purpose of confirming the histologic diagnosis and for biomarker analysis.
•Sponsor preapproval is required when a biopsy procedure is needed for the sole purpose of determining study eligibility. Biopsies of the lung/mediastinum, pancreas, or endoscopic procedures extending beyond the esophagus, stomach, or bowel may not be performed for the sole purpose of determining study eligibility.
•- A genomic defect in a DNA repair gene that is likely to or that may sensitize to PARP inhibition as assessed by a gene mutation biomarker panel.
•- Serum testosterone = 1.73 nmol/L (50 ng/dL) at screening.
•- Bilateral orchiectomy or ongoing androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH) agonist/antagonist (surgical or medical castration).
•- Progressive disease at study entry defined as 1 or more of the following 3 criteria:
•A minimum of 3 rising PSA values with an interval of at least 1 week between determinations. The screening central laboratory PSA value must be = 2 µg/L (2 ng/mL) if qualifying solely by PSA progression.
•Soft tissue disease progression as defined by RECIST 1.1.
•Bone disease progression defined by PCWG3 with 2 or more new metastatic lesions on bone scan.
•- Metastatic disease with measurable soft tissue disease by CT or MRI per RECIST 1.1. Patients with disease spread limited to regional pelvic lymph nodes (below the aortic bifurcation) are not eligible. Patients may also have metastatic disease documented by bone lesions on whole body radionuclide bone scan.
•- Previous treatment with 1 or 2 chemotherapy regimens including at least 1 taxane-based regimen for metastatic prostate cancer. Patients may have received radium-223 and/or cabazitaxel, or were deemed unsuitable, declined, or did not have access to these therapies.
•- A history of disease progression during previous treatment for metastatic CRPC with at least 1 novel hormonal therapy (enzalutamide and/or abiraterone acetate/prednisone) in the opinion of the investigator.
•-Bisphosphonate or denosumab dosage must have been stable for at least 4 weeks before day 1 for patients receiving these therapies.
•- ECOG performance status of 0 to 2.
•-Estimated life expectancy of = 6 months.
•-Able to swallow the study drug, have no known intolerance to study drugs or excipients, and comply with study requirements.
•-Must use a condom when having sex with a pregnant woman or with a woman of childbearing potential from the time of the first dose of study drug through 105 days after last dose of study drug. Contraception should be considered for a nonpregnant female partner of childbearing potential.
•-Must agree not to donate sperm from the first dose of study drug to 105 days after the last dose of study drug.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 50
•F.1.3 Elderly (>=65 years) yes

排除标准

•- Use of systemic hormonal, biologic, or radionuclide therapy for treatment of metastatic prostate cancer (other than approved bone-targeting agents and GnRH agonist/antagonist) or any other investigational agent within 4 weeks before day 1.
•- Prior treatment with a PARP inhibitor, platinum, cyclophosphamide, or mitoxantrone chemotherapy.
•- Radiation therapy within 3 weeks (within 2 weeks, if single fraction of radiotherapy) before day 1.
•- Major surgery within 2 weeks before day 1.
•- Clinically significant cardiovascular disease, including any of the following:
•Myocardial infarction or symptomatic cardiac ischemia within 6 months before screening.
•Congestive heart failure New York Heart Association class III or IV.
•History of clinically significant ventricular arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes).
•History of Mobitz II second degree or third degree heart block unless a permanent pacemaker is in place.
•Hypotension as indicated by systolic blood pressure < 86 mm Hg at screening.
•Bradycardia as indicated by a heart rate of < 45 beats per minute on the screening electrocardiogram.
•Uncontrolled hypertension as indicated by systolic blood pressure > 170 mm Hg or diastolic blood pressure > 105 mm Hg at screening.
•- Significant organ dysfunction as defined by the following laboratory abnormality:
•Renal: eGFR < 30 mL/min /1.73 m2 by the MDRD equation (Modification of Diet in Renal Disease [available via www.mdrd.com]).
•– Total serum bilirubin > 1.5 times the upper limit of normal (ULN) (> 3 times ULN for patients with Gilbert syndrome or for whom indirect bilirubin concentrations suggest an extrahepatic source of elevation)
•– Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) = 2.5 times ULN (if liver test abnormalities are due to hepatic metastasis, then AST or ALT = 5 × ULN)
•– Albumin < 3.0 g/dL
•Bone marrow reserve: absolute neutrophil count < 1500/µL, platelets < 100,000/µL, or hemoglobin < 9 g/dL (NOTE: may not have received growth factors or blood transfusions within 14 days before obtaining the hematology values at screening).
•- Known or suspected brain metastasis or active leptomeningeal disease.
•- Symptomatic or impending spinal cord compression or cauda equina syndrome.
•- Diagnosis of MDS.
•- History of another cancer within 3 years before enrollment with the exception of nonmelanoma skin cancers, or American Joint Committee on Cancer stage 0 or stage 1 cancer that has a remote probability of recurrence in the opinion of the investigator and the sponsor.
•- Gastrointestinal disorder affecting absorption.
•- Current or anticipated use of a strong P-gp inhibitor (eg, dronedarone, quinidine, ranolazine, itraconazole, ketoconazole), strong P-gp inducer (eg, rifampin, tipranavir, ritonavir), or strong inhibitor of BCRP (eg, elacridar [GF120918]).
•- Any other condition (concurrent disease, infection, or comorbidity) that interferes with ability to participate in the study, causes undue risk, or complicates the interpretation of data, in the opinion of the investigator or medical monitor.

研究者

发起方

Medivation, Inc.

相似试验

进行中（未招募）

1 期

An international study to evaluate the effectiveness of Talazoparib in men with a genomic defect and metastatic castration-resistant prostate cancer who received previous chemotherapy and progressed on hormonal treatmentMen With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone)MedDRA version: 19.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-002036-32-ESMedivation, Inc.150

进行中（未招募）

1 期

An international study to evaluate the effectiveness of Talazoparib in men with a genomic defect and metastatic castration-resistant prostate cancer who received previous chemotherapy and progressed on hormonal treatmentMen With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone)MedDRA version: 19.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-002036-32-FRMedivation, Inc.150

进行中（未招募）

不适用

A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally At A Dose of 800 mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients with Unresectable, Locally Advanced or Metastatic Hepatocellular CarcinomaRevised Protocol Number 01, incorporating Amendment 02+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific, version 1.0 dated 29-Apr-06nresectable, advanced or metastatic hepatocellular carcinomaMedDRA version: 8.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectable

EUCTR2006-001012-68-GBBristol-Myers Squibb International Corporation130

进行中（未招募）

1 期

EUCTR2006-001012-68-FRBristol-Myers Squibb International Corporation130

进行中（未招募）

1 期

Open-label, randomized study of two doses of GSK2857916 in participants with relapsed/refractory multiple myeloma who have failed prior treatment with an anti-CD38 antibodyRelapsed/Refractory Multiple MyelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864

EUCTR2017-004810-25-ESGlaxoSmithKline, S.A.221